cp-533,536
Small moleculeexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 2008 (NCT00533377)
Timeline
2000s
- Jan 1, 2008
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Prostanoid EP2 receptorAGONIST
PTGER2 agonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- (3-((4-tert-butylbenzyl)-(pyridine-3-sulfonylamino)methyl)phenoxy)acetic acid
- cp533536
- cp-533,536
- cp-533,536
- cp-533,536
- cp-533, 536
- cp-533, 536
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00533377 | Phase 2 | Jan 1, 2008 | Pfizer |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Pfizer | For profit | 1 | 1 | 1 | 2008 |
1 organizations
Page 1 / 1